Lapatinib

Type: Keyphrase
Name: Lapatinib
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

[Comment] Dual targeting of HER2 with lapatinib and trastuzumab

Drugs targeting HER2 are central to the treatment of patients with HER2-positive breast cancer, and dual targeting of HER2 with two drugs has gained much attention since 2010. 1 Patients with metastatic HER2-positive breast cancer have better overall ... [Published Lancet Oncology - Sep 02 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib - Abstract

Lapatinib, a dual tyrosine kinase inhibitor of ErbB1 and ErbB2, shows a clinical benefit in a subset of patients with advanced urothelial bladder cancer (UBC).We hypothesized that the corresponding gene, ERBB2, is affected by mutations in a subset of ... [Published UroToday - Aug 28 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

NHI will cover new cancer drug

A new orally administered targeted therapy for metastatic breast cancer that has spread to the brain is to be covered by the National Health Insurance (NHI) program, in an effort to substantially reduce patients’ medical costs, the NHI Administration ... [Published Taipei Times Online - Aug 26 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

How We Treat Patients with Gastric Cancer

Elimova, Elena MD, MSC; Badgwell, Brian MD; Das, Prajnan MD, MS, MPH; Estrella, Jeannelyn MD; Matamoros, Aurelio MD; Ajani, Jaffer A. MDImage ToolsGastric cancer represents a serious health problem on a global scale. It is the second leading cause of ... [Published Oncology Times - Aug 22 2014]
First reported Aug 16 2014 - Updated Aug 16 2014 - 1 reports

Comment Dual targeting of HER2 with lapatinib and trastuzumab

Relevant TopicsBreast CancerLatest News Clinical Trials Research Drugs Reports CorporateTrack and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical ... [Published BioPortfolio - Aug 16 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials

1 Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France2 Université Paris Sud, Faculté de Médecine, Kremlin Bicêtre, FranceFor all author emails, please log on.BMC Medicine 2014, 12:132 doi:10.1186/s12916-014-0132-3The electronic ... [Published BMC - Aug 12 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Advances in treating HER2-positive breast cancer: an interview with Sunil Verma

Dr Sunil Verma (Figure  1 ) is a medical oncologist who is internationally recognized for his research and educationleadership in breast cancer. He is the principal investigator for many clinical trialsin breast and lung cancer, and has led pioneering ... [Published BMC - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 1 reports

Kadcyla: NICE disappointed by manufacturer's decision

Ratings require JavaScript to be enabled.The National Institute for Health and Care Excellence (NICE) is very disappointed that Roche, the manufacturer of Kadcyla (trastuzumab emtansine) has decided not to offer its new treatment at a price that would ... [Published Medical News Today - Aug 11 2014]
First reported Aug 10 2014 - Updated Aug 10 2014 - 1 reports

Key Breast Cancer Takeaways from ASCO 2014

MD, PHDCYNTHIA X. MA, MD, PHDImage ToolsASCO 2014 marked another successful year of progress in breast cancer clinical research. We are now armed with better treatment options to consider for our patients and more in-depth understanding of breast cancer ... [Published Oncology Times - Aug 10 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 3 reports

NICE rejects breast cancer drug because too costly

The National Institute for Health and Care Excellence (NICE) is not recommending Kadcyla (trastuzumab emtansine) for routine use by the NHS for advanced breast cancer on the NHS because it is too costly.The watchdog said that it was very disappointed ... [Published OnMedicanet - Aug 08 2014]
First reported Aug 06 2014 - Updated Aug 07 2014 - 1 reports

Study Findings from Fudan University Broaden Understanding of Gliomas (In vivo behavior and safety of lapatinib-incorporated lipid nanoparticles)

By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Oncology have been published. According to news originating from Shanghai , People's Republic of China , by NewsRx correspondents, research stated, "To improve the solubility, ... [Published HispanicBusiness.com - Aug 06 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months' Remission with Lapatinib plus Capecitabine

ReferencesGroves MD: New strategies in the management of leptomeningeal metastases. Arch Neurol 2010;67:305-312.Lai R, Dang CT, Malkin MG, Abrey LE: The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. ... [Published Sexual Development - Aug 06 2014]

Quotes

...independent predictor," Mamounas, the medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, said. "Our findings have clinical implications relative to further tailoring the use of adjuvant radiotherapy after neoadjuvant chemotherapy and further support the conduct of ongoing clinical trials that attempt to tailor locoregional therapy in the neoadjuvant chemotherapy setting."
...In the subjects with the highest antibody concentrations, the authors note "some patients demonstrated a strong anti-drug antibody response after about 10 days of cycle 2 dosing, with an abrupt reduction of bioavailability and increase in drug clearance."
...According to news reporting originating from Uppsala, Sweden , by NewsRx correspondents, research stated, "Resistance has been reported to human epidermal growth factor receptor 2 (HER2)-targeted therapy with the tyrosine kinase inhibitor lapatinib and the antibody trastuzumab in metastatic gastric cancer. An alternative or complement might be to target the extracellular domain of HER2 with therapy-effective radionuclides."
"We are really disappointed that Roche were not able to demonstrate more flexibility to help us provide a positive recommendation. The company is well aware that we could not recommend Kadcyla at the price it proposed."

More Content

All (50) | News (45) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Subtype, pCR Predict Locoregional Recurrence Fo... [Published OncLive - 1 hour ago]
[Comment] Dual targeting of HER2 with lapatinib... [Published Lancet Oncology - Sep 02 2014]
MacroGenics: A Late Stage Pipeline Review [Published Seeking Alpha - Aug 30 2014]
Impact of ERBB2 mutations on in vitro sensitivi... [Published UroToday - Aug 28 2014]
Researchers from Uppsala University Describe Fi... [Published HispanicBusiness.com - Aug 28 2014]
NHI will cover new cancer drug [Published Taipei Times Online - Aug 26 2014]
How We Treat Patients with Gastric Cancer [Published Oncology Times - Aug 22 2014]
Top 3 lessons learned from ICE/ENDO 2014 [Published Orthopedics Today - Aug 19 2014]
Comment Dual targeting of HER2 with lapatinib a... [Published BioPortfolio - Aug 16 2014]
Takeaways from the ASCO Annual Meeting from Gor... [Published Oncology Times - Aug 14 2014]
Favorable Safety Profile of T-DM1 Confirmed in ... [Published OncLive - Aug 13 2014]
Tripathy Offers Perspective on HER2-Positive Br... [Published OncLive - Aug 13 2014]
Rice Quantum Institute rewards top students at ... [Published Rice University - Aug 12 2014]
Strategies to overcome trastuzumab resistance i... [Published BMC - Aug 12 2014]
Advances in treating HER2-positive breast cance... [Published BMC - Aug 12 2014]
NICE rejects Roche’s new breast cancer drug ove... [Published Pharmaceutical Technology - Aug 11 2014]
Kadcyla: NICE disappointed by manufacturer's de... [Published Medical News Today - Aug 11 2014]
Key Breast Cancer Takeaways from ASCO 2014 [Published Oncology Times - Aug 10 2014]
NICE rejects breast cancer drug because too costly [Published OnMedicanet - Aug 08 2014]
Storm brewing over Roche cancer drug price [Published Pharmafocus - Aug 08 2014]
ROCHE BEARER SHARE : NICE -Pressure grows on Ro... [Published 4 Traders - Aug 08 2014]
Study Findings from Fudan University Broaden Un... [Published Wall Street Business Network - Aug 07 2014]
Study Findings from Fudan University Broaden Un... [Published HispanicBusiness.com - Aug 06 2014]
Brain Metastases of Her2-Positive Breast Cancer... [Published Sexual Development - Aug 06 2014]
Examining the Protective Role of ErbB2 Modulati... [Published Toxicological Sciences - Aug 05 2014]
ALTTO Fallout Focuses Debate on the Meaning of pCR [Published American Journal of Public Health - Jul 29 2014]
BPA Free Microwave Cover Serves as Safe Substit... [Published Scoop Asia - Jul 29 2014]
Clinical Trials and Studies: ALTTO test of dual... [Published NewsRX - Jul 29 2014]
Drugs to Avoid in Patients on Tyrosine Kinase I... [Published Diabetes Care - Jul 25 2014]
Neratinib Comes Through For Puma [Published In the Pipeline - Jul 23 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Neratinib Comes Through For Puma [Published In the Pipeline - Jul 23 2014]
Yet another entry in the "Why do people keep investing in biopharma?" files. Take a look at the case of Puma Biotechnology. Their stock was as high as $140/share earlier in the year, and it gradually deflated to the high 50s/low 60s as time went on. ...
GSK's Phase III trial of breast cancer combinat... [Published PBR - News - Jun 02 2014]
UK-based drug maker GlaxoSmithKline (GSK) has reported results from its Phase III trial of two anti-HER2 agents, lapatinib (Tykerb/Tyverb) and trastuzumab, as an adjuvant treatment for patients with HER2 positive primary breast cancer. ...
Cost Control in the UK [Published Balloon Juice - Apr 23 2014]
Via the Guardian: A Herceptin-style drug that can offer some women with advanced breast cancer nearly six months of extra life has been turned down for use in the NHS because of its high cost. In draft guidance now open to consultation, the ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Apr 01 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.